Board Chair Warns Vaccine Clinic Threatens Hospital Reputation
NIH Clinical Center leadership argues the new facility adds no budget or space while risking the institution's standing among rare disease patients.
By Jason Kovalenko ·
Six minutes. That is how long Jack Leslie, chair of the board overseeing the National Institutes of Health Clinical Center Research Hospital, spent delivering a direct critique of Health Secretary Robert F. Kennedy Jr. during a recent regularly scheduled meeting. Leslie paused the standard agenda and friendly introductions to address what he viewed as a serious threat to the institution's public image.
The controversy centers on the opening of a vaccine injury clinic at the hospital. Kennedy arrived for a surprise ribbon-cutting ceremony accompanied by high-ranking Trump administration officials. A panel of attendees sat behind placards labeled "vaccine injured," sharing their stories of alleged harm. Leslie argued that this public display risked tarnishing a hospital widely known as the "house of hope." That nickname reflects its role as a final destination for patients with rare conditions who have exhausted other treatment options.
Leslie stated that some board members might prefer he remain silent about the Secretary's activities. He rejected that approach, arguing that silence would be a failure of the advisory board's duty. "But I think that that would be a failing as an advisory board if we were silent," he said. He clarified that his objection was not to the science of studying vaccine harms. He noted that serious reactions are rare but real and insisted that people who believe they have been injured must be taken seriously.
The financial and physical footprint of the new clinic is minimal. The NIH already operates a center dedicated to studying vaccine injuries. The new facility launched with no additional funding and no extra clinic space. Jonathan Green, the hospital's CEO, sat beside Leslie during the meeting and supported this assessment. Green explained that the NIH has researched vaccine safety and efficacy for decades and that this work continues. He described the new clinic as just one more individual "protocol" within the hospital's existing research framework.
The two leaders presented a distinct contrast in how they viewed the launch. Leslie framed the issue as a reputational risk for an institution serving vulnerable patients. Green presented it as a modest administrative addition to long-standing research. The board's reaction highlights the tension between the high-profile political nature of the launch and the clinic's modest practical impact on the hospital's operations and budget.
